A New Technology for Rapid Therapy Guidance (Webinar Recording)

𝗔 𝗡𝗲𝘄 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗳𝗼𝗿 𝗥𝗮𝗽𝗶𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗚𝘂𝗶𝗱𝗮𝗻𝗰𝗲 webinar introduces a new cancer therapy guidance test designed to predict which cancer drugs are most likely to be effective for individual cancer patients. Presenters: Clifford Reid, PhD | Founder and CEO, Travera Dennis Watson | VP of Business Development, Travera Kaumudi Bhawe, PhD | Scientist, Cancer Commons The event was held virtually on December 14, 2022. Cancer Commons is partnering with Travera (https://www.travera.com/) with the shared goal of helping late-stage cancer patients who are running out of therapeutic options and time. While the FDA has approved many drugs to treat specific cancers, every cancer patient’s cells are unique. Not all approved drugs work for all people at every cancer stage. Travera uses a single-cell measurement technology invented at MIT to measure the ex vivo growth response of live tumor cells to candidate drugs. Their 2-day Rapid Therapy Guidance™ test enables patients who are running out of therapeutic options to discover additional options and continue their battle against cancer. 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗜𝗻𝗾𝘂𝗶𝗿𝗶𝗲𝘀, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗰𝗼𝗻𝘁𝗮𝗰𝘁: 𝗗𝗲𝗻𝗻𝗶𝘀 𝗪𝗮𝘁𝘀𝗼𝗻 | 𝗱𝘄𝗮𝘁𝘀𝗼𝗻@𝘁𝗿𝗮𝘃𝗲𝗿𝗮.𝗰𝗼𝗺 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 𝗮𝗯𝗼𝘂𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗺𝗺𝗼𝗻𝘀 𝘄𝗲𝗯𝗶𝗻𝗮𝗿𝘀: 𝗲𝗱𝘂𝗰𝗮𝘁𝗶𝗼𝗻@𝗰𝗮𝗻𝗰𝗲𝗿𝗰𝗼𝗺𝗺𝗼𝗻𝘀.𝗼𝗿𝗴​ 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗺𝗺𝗼𝗻𝘀 𝗳𝗿𝗲𝗲 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀: 𝗵𝘁𝘁𝗽𝘀://𝗰𝗮𝗻𝗰𝗲𝗿𝗰𝗼𝗺𝗺𝗼𝗻𝘀.𝗼𝗿𝗴/𝗴𝗲𝘁-𝗵𝗲𝗹𝗽 Please connect with Cancer Commons on social media:   / cancercommons     / cancercommons     / cancercommons     / cancercommons